As a result, we identified two shared axes of variation for colorectal cancer organoid morphology (organoid size and cystic vs. solid architecture), their underlying biological mechanisms (IGF1R signaling and Wnt signaling), and pharmacological interventions able to move organoids along them (mTOR inhibition and MEK inhibition). This evidence concerns the gene MTOR and colorectal cancer.